
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is a promising investment opportunity due to its strong financial situation, with the recent FDA approvals of Vyvgart and Vyvgart Hytrulo for multiple autoimmune diseases, as well as ongoing clinical trials for multiple indications. The company's innovative approach to targeting antibody-driven immune disorders, as shown by its pipeline of potential treatments, also bodes well for its future success. Furthermore, the positive data from the Phase 3 ALKIVIA trial for Vyvgart in myositis and the potential for a label expansion to include DM only add to the company's promising outlook.
Bears say
argenx is a Dutch biopharmaceutical company with a strong focus on research and development of antibody-based treatments for rare autoimmune diseases. Despite recent FDA approvals for its lead product Vyvgart/efgartigimod, there is potential for market competition with new products in development by other companies. Additionally, the success of ARGX is heavily reliant on the outcomes of clinical trials and regulatory approvals, and any setbacks could negatively impact its revenue growth and stock price. There are also potential risks in securing and maintaining patent protection, as well as potential pricing pressure. Overall, the company's stock may face challenges in the future and its current valuation may not fully reflect these risks.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares